<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820599</url>
  </required_header>
  <id_info>
    <org_study_id>2008-04</org_study_id>
    <nct_id>NCT00820599</nct_id>
  </id_info>
  <brief_title>Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)</brief_title>
  <acronym>PREVAIL-TF</acronym>
  <official_title>Transfemoral Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (EUROPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating
      the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; &quot;study valve&quot;), its
      transfemoral delivery system, and crimper accessories. The trial includes a premarket
      confirmatory cohort to evaluate the system performance as well as a Post Market Clinical
      Follow-up phase involving expanded enrollment and long-term follow-up of all patients to
      evaluate valve performance out to 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Edwards Lifesciences obtained CE marking authorization for transfemoral delivery /
      implantation of the Edwards SAPIEN™ transcatheter heart valve (model 9000TFX) using the
      RetroFlex™ delivery system in August 2007 and introduced these devices for commercial
      distribution in the European Economic Area (EEA) in October 2007.

      Clinical Sites: Up to 11 sites in Europe
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint: Freedom from death at 30 days from the index procedure</measure>
    <time_frame>30 days from the index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from vascular complications, stroke, myocardial infarction, reintervention, valve embolization, conduction defects requiring permanent pacemaker, aortic regurgitation, perivalvular leak</measure>
    <time_frame>30 days from the index procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transaortic Valve Replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sapien XT™ transcatheter heart valve and delivery system</intervention_name>
    <arm_group_label>TAVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All candidates for this study must meet all of the following inclusion criteria:

          1. Patients must have co-morbidities such that the surgeon (Co Investigator) and
             interventional cardiologist (Principal Investigator) concur that the predicted risk of
             operative mortality is &gt; 15% with a minimum STS Risk Calculator score of ≥ 10 and/or
             Logistic EuroSCORE of &gt; 20%.

          2. Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA
             Functional Class II or greater.

          3. The subject or the subject's legal representative has been informed of the nature of
             the study, agrees to its provisions and has provided a written informed consent that
             has been approved by the reviewing Ethics Committee (EC) of the respective clinical
             site.

          4. Subject is willing to comply with specified follow up evaluations, including possible
             coronary angiography and transesophageal echocardiography.

          5. The subject and the treating physician agree that the subject will return for all
             required post-procedure follow-up visits.

        Exclusion Criteria:

          1. Aortic valve is a congenital unicuspid or bicuspid valve, or is non-calcified.

          2. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
             aortic regurgitation &gt;3+).

          3. Any therapeutic invasive cardiac procedure, other than BAV, performed within 30 days
             of the index procedure (or 6 months if the procedure was a drug eluting coronary stent
             implantation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Stefan Sack</last_name>
    <role>Study Director</role>
    <affiliation>Cardiology Clinic of Schwabing Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Fourthin</last_name>
    <role>Study Director</role>
    <affiliation>Edwards Lifesciences SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ornze Lieve Vrouwziekenhuis (OLVZ) Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hospital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toolouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinics Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76185</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04829</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwabing Clinic</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital - NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital - NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sapien Valve</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Heart Valve Therapy</keyword>
  <keyword>Transfemoral</keyword>
  <keyword>Transcatheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

